SVB Securities Thinks BioNTech SE’s Stock is Going to Recover

In a report released today, Daina Graybosch from SVB Securities maintained a Buy rating on BioNTech SE (BNTXResearch Report), with a price target of $224.00. The company’s shares closed last Thursday at $164.92, close to its 52-week low of $117.08.

According to TipRanks.com, Graybosch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.1% and a 32.4% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Werewolf Therapeutics, Century Therapeutics, and Bolt Biotherapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNTech SE with a $221.30 average price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $464.00 and a one-year low of $117.08. Currently, BioNTech SE has an average volume of 1.14M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.

Read More on BNTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More